News | September 25, 2022
Aptar Pharma collaborates with Fluidda
The companies will leverage their respective proprietary technology platforms
The companies will leverage their respective proprietary technology platforms
Krsnaa Diagnostics plans to set up Tele-Pathology Reporting Centre in Pune
Witnessing sizable consolidation (M& A) activity with Domestic Formulations and Hospitals being two areas wherein maximum M&A has occurred.
First and only biologic approved in the EU in patients with severe asthma with no phenotype or biomarker limitations
The objective of this study is to evaluate the efficacy of ASC22 (Envafolimab) combined with Chidamide on the viral reservoirs of latently infected cells in HIV patients.
Rymti is indicated in the treatment of rheumatoid arthritis, juvenile idiopathic arthritis, psoriatic arthritis, axial spondyloarthritis, plaque psoriasis, and paediatric plaque psoriasis
The reliability of their products, evidenced by their inclusion in the WHO emergency use list, has further improved with the addition of Takara Bio's enzymes.
The programme will see participation from various ministries of the Government of India with the aim of 3Js – Jan Sandesh, Jan Bhagidari, and Jan Aandolan.
Healthcare has become more focused on innovation and technology over the past two years and 80% of healthcare systems are aiming to increase their investment in digital healthcare tools in the coming five years
New data from Boehringer Ingelheim support the potential use of nintedanib in children and adolescents with fibrosing interstitial lung disease
Subscribe To Our Newsletter & Stay Updated
